Phase I Trial of Carboplatin and Weekly Paclitaxel in Patients With Advanced Non-small-cell Lung Cancer

Objective: This study was designed to determine the maximum tolerated dose of paclitaxel administered weekly in combination with carboplatin and to assess its dose limiting toxicity and preliminary activity in patients with previously untreated, advanced non-small-cell lung cancer. Methods:Carboplatin was administered at a fixed dose that maintained an area under the curve of 6. Paclitaxel was given over 1 h once a week for 3 weeks starting at 60 mg/m2 and escalated in 10 mg/m2 increments